Welcome to our dedicated page for Annovis Bio SEC filings (Ticker: ANVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Annovis Bio, Inc. filings document the regulatory record of a clinical-stage biotechnology company developing buntanetap for Alzheimer’s disease, Parkinson’s disease, and related neurodegenerative conditions. Recent Form 8-K reports cover operating results, Regulation FD materials, clinical and regulatory updates, material-event disclosure, exhibits, and changes in executive finance leadership.
Proxy materials describe annual-meeting proposals, director elections, stockholder voting procedures, board governance, and the company’s common stock structure. The filings also identify ANVS common stock as a New York Stock Exchange-listed security and provide capital-structure and governance disclosures relevant to the company’s development-stage business.
Annovis Bio (ANVS) Vice President of Finance Andrew Walsh reported a new acquisition of company shares on Form 4. The transaction details include:
- Acquired 500 shares of Common Stock
- Purchase price: $2.90 per share
- Transaction date: June 16, 2025
- Total transaction value: $1,450
- Ownership type: Direct
Following this transaction, Walsh holds 500 shares directly. The purchase represents an initial position for the executive, as no prior holdings were reported. The transaction was reported within the required two-business-day filing window, with the Form 4 being filed on June 28, 2025. No derivative securities were involved in this transaction.